Aliases & Classifications for Joint Disorders

MalaCards integrated aliases for Joint Disorders:

Name: Joint Disorders 37 40
Arthropathy 69

Summaries for Joint Disorders

MedlinePlus : 40 A joint is where two or more bones come together, like the knee, hip, elbow, or shoulder. Joints can be damaged by many types of injuries or diseases, including Arthritis - inflammation of a joint. It causes pain, stiffness, and swelling. Over time, the joint can become severely damaged. Bursitis - inflammation of a fluid-filled sac that cushions the joint Dislocations - injuries that force the ends of the bones out of position Treatment of joint problems depends on the cause. If you have a sports injury, treatment often begins with the RICE (Rest, Ice, Compression, and Elevation) method to relieve pain, reduce swelling, and speed healing. Other possible treatments include pain relievers, keeping the injured area from moving, rehabilitation, and sometimes surgery. For arthritis, injuries, or other diseases, you may need joint replacement surgery to remove the damaged joint and put in a new one. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Joint Disorders, also known as arthropathy, is related to osteoarthritis and rheumatic disease, and has symptoms including stiffness of joint, not elsewhere classified in icd10cm, joint symptom and other symptoms referable to joint, site unspecified. An important gene associated with Joint Disorders is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Etanercept and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and eye, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Joint Disorders

Diseases related to Joint Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 203)
# Related Disease Score Top Affiliating Genes
1 osteoarthritis 29.3 IL1B IL6 MMP3 TIMP1 TNF TNFSF11
2 rheumatic disease 29.3 IL1B IL1R1 TNF
3 osteomyelitis 29.1 IL1B IL1RN IL6 TNF TNFSF11
4 psoriatic arthritis 29.0 IL17A IL1B MMP3 TNF TNFSF11
5 juvenile rheumatoid arthritis 28.9 IL1B IL1R1 IL1RN IL6 TNF
6 arthritis 28.4 CSF1 IL17A IL1B IL1RN IL6 MMP3
7 rheumatoid arthritis 27.0 CSF1 IL11 IL17A IL1B IL1R1 IL1RN
8 osteoporosis 26.5 CSF1 DKK1 IL11 IL1B IL1RAPL2 IL1RN
9 scorpion envenomation 10.6 IL6 TNF
10 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL6 TNF
11 critical limb ischemia 10.5 IL6 TNF
12 osteochondritis dissecans 10.5
13 adenosine monophosphate deaminase 1 deficiency 10.5
14 crystal arthropathies 10.5
15 familial osteochondritis dissecans 10.5
16 lymph node disease 10.5 IL6 MMP3 TNF
17 exostosis 10.4
18 transverse myelitis 10.4 IL17A IL6 TNF
19 conjunctivochalasis 10.4 MMP3 PLAU TIMP1
20 myelitis 10.4 IL17A IL6 TNF
21 stromal keratitis 10.4 IL17A IL6 TNF
22 gingival overgrowth 10.4 IL6 MMP3 TIMP1
23 brucellosis 10.4 IL1RN IL6 TNF
24 ileitis 10.4 IL17A IL6 TNF
25 takayasu arteritis 10.4 IL6 MMP3 TNF
26 echinococcosis 10.4 IL17A IL6 TNF
27 reactive arthritis 10.4 IL17A IL6 TNF
28 rheumatoid lung disease 10.4 IL17A MMP3 TNF
29 post-transplant lymphoproliferative disease 10.4 IL1R1 IL6 TNF
30 polyposis, gastric 10.4 IL1B TNF
31 periventricular leukomalacia 10.4 IL1R1 IL6 TNF
32 breast adenocarcinoma 10.4 PLAU TNF TNFSF11
33 acute cholangitis 10.4 IL1RN IL6
34 streptococcal toxic-shock syndrome 10.4 IL6 TNF
35 spondylitis 10.4 IL17A IL6 TNF
36 cryopyrin-associated periodic syndrome 10.3 IL1R1 IL1RN IL6
37 recurrent corneal erosion 10.3 IL1B IL6
38 squamous cell carcinoma of the hypopharynx 10.3 MMP3 TIMP1
39 null-cell leukemia 10.3 IL6 TNF
40 systemic onset juvenile idiopathic arthritis 10.3 IL1B TNF
41 arthropathy 10.3
42 radiculopathy 10.3 IL17A IL1R1 IL6
43 myocarditis 10.3 IL17A IL6 TNF
44 bagassosis 10.3 IL1B IL6
45 kawasaki disease 10.3 IL6 MMP3 TIMP1 TNF
46 periodontitis, chronic 10.3 IL1B IL6 TNFSF11
47 multicentric reticulohistiocytosis 10.3 CSF1 TNFSF11
48 laryngitis 10.3 IL1B IL6 TNF
49 staphylococcal toxic shock syndrome 10.3 IL1B TNF
50 acute vascular insufficiency of intestine 10.3 IL1B IL6 TNF

Graphical network of the top 20 diseases related to Joint Disorders:



Diseases related to Joint Disorders

Symptoms & Phenotypes for Joint Disorders

UMLS symptoms related to Joint Disorders:


stiffness of joint, not elsewhere classified in icd10cm, joint symptom, other symptoms referable to joint, site unspecified, musculoskeletal symptom, joint stiffness, other symptoms referable to joint, multiple sites, other symptoms referable to joint, other specified sites, other symptoms referable to joint, ankle and foot, other symptoms referable to joint, lower leg, other symptoms referable to joint, pelvic region and thigh, other symptoms referable to joint, hand, other symptoms referable to joint, forearm, other symptoms referable to joint, upper arm, other symptoms referable to joint, shoulder region, other symptoms referable to joint, sciatica, muscle cramp, metatarsalgia, back pain, arthralgia

GenomeRNAi Phenotypes related to Joint Disorders according to GeneCards Suite gene sharing:

25 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.55 CSF1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.55 CSF1 TNFSF11
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.55 TNFSF11
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.55 IL1RN
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-175 9.55 TNFSF11
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.55 TNFSF11 CSF1 IL18R1 IL1RN PLAU
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.55 PLAU
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.55 IL18R1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.55 PLAU
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.55 CSF1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.55 CSF1 TNFSF11

MGI Mouse Phenotypes related to Joint Disorders:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 SERPINB2 IL6R TIMP1 MMP3 TNF PLAU
2 growth/size/body region MP:0005378 10.29 IL6 SERPINB2 IL6R TIMP1 PLAU TNF
3 homeostasis/metabolism MP:0005376 10.28 IL6 SERPINB2 IL6R TIMP1 MMP3 TNF
4 immune system MP:0005387 10.25 SERPINB2 IL6R TIMP1 MMP3 TNF PLAU
5 endocrine/exocrine gland MP:0005379 10.15 IL6 IL6R TIMP1 PLAU TNF TNFSF11
6 mortality/aging MP:0010768 10.13 IL6 SERPINB2 IL6R TIMP1 PLAU TNF
7 craniofacial MP:0005382 10.11 PLAU TNF TNFSF11 IL1R1 IL17A IL1B
8 integument MP:0010771 9.97 PLAU IL6 TNF TNFSF11 IL1R1 IL1RN
9 neoplasm MP:0002006 9.81 IL6 SERPINB2 IL6R TIMP1 TNF PLAU
10 muscle MP:0005369 9.8 PLAU IL6 SERPINB2 TNF TNFSF11 IL1R1
11 respiratory system MP:0005388 9.61 IL6 TIMP1 TNF PLAU TNFSF11 IL17A
12 skeleton MP:0005390 9.4 TIMP1 MMP3 TNF PLAU IL6 TNFSF11

Drugs & Therapeutics for Joint Disorders

Drugs for Joint Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 912)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
2
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 9004-61-9 53477741 24759
3
Azithromycin Approved Phase 4,Phase 3 83905-01-5 53477736 447043 55185
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
5
Thrombin Approved, Investigational Phase 4
6
Bevacizumab Approved, Investigational Phase 4 216974-75-3
7
Menthol Approved Phase 4,Phase 3,Phase 2,Early Phase 1 2216-51-5 16666
8
Iron Approved Phase 4,Phase 1,Phase 2 7439-89-6 23925
9
Rivaroxaban Approved Phase 4,Phase 2,Phase 3 366789-02-8
10
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1 1197-18-8 5526
11
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
12
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2 169590-42-5 2662
13
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 1 161796-78-7, 119141-88-7 9579578 4594
14
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22204-53-1 156391 1302
15
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 38396-39-3, 2180-92-9 2474
16
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
17
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
18
Ropivacaine Approved Phase 4,Phase 3,Phase 2 84057-95-4 175805 71273
19
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1 615258-40-7
20
Cimetidine Approved, Investigational Phase 4,Phase 3,Phase 2 51481-61-9 2756
21
Hyoscyamine Approved Phase 4 101-31-5 64692
22
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
23
Norepinephrine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-41-2 439260
24
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 103-90-2 1983
25
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2 118-42-3 3652
26
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
27
Sulfasalazine Approved Phase 4,Phase 2,Phase 3,Phase 1 599-79-1 5359476 5353980
28
Leflunomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75706-12-6 3899
29
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 331731-18-1 16219006
30
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1 170277-31-3
31
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 15307-86-5 3033
32
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 202409-33-4 123619
33
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1 332348-12-6 10237
34
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
35
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83-43-2 6741
36
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 16590-41-3 5360515
37
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-24-8 5755
38
Anastrozole Approved, Investigational Phase 4,Phase 2 120511-73-1 2187
39
Letrozole Approved, Investigational Phase 4,Phase 2 112809-51-5 3902
40
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
41
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2 51-43-4 5816
42
Ketorolac Approved Phase 4,Phase 3,Phase 2 74103-06-3, 66635-83-4 3826
43
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2 57-27-2 5288826
44 Racepinephrine Approved Phase 4,Phase 3,Phase 2 329-65-7
45
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2 471-34-1
46
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
47
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
48
Pamidronate Approved Phase 4 40391-99-9 4674
49
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 124-94-7 31307
50
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 137-58-6 3676

Interventional clinical trials:

(show top 50) (show all 6794)

# Name Status NCT ID Phase Drugs
1 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
2 Hyaluronan Versus NaCl 20 Ml Versus Placebo in Knee Osteoarthritis Unknown status NCT00144820 Phase 4 Injection of Hyaluronan or Saline
3 The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
4 The Effect of Biannual Monitoring With Magnetic Resonance Imaging (MRI), X-ray, or Usual Care on Treatment for Inflammatory Arthritis Unknown status NCT00808496 Phase 4
5 Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens Unknown status NCT02314325 Phase 4 ADVATE [Antihemophilic Factor (Recombinant)];ADVATE [Antihemophilic Factor (Recombinant)]
6 Birmingham Hip Resurfacing (BHR) Study: Implantation of a Hip Resurfacing Endoprosthesis Unknown status NCT00180206 Phase 4
7 Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery Unknown status NCT00983112 Phase 4 Human Fibrinogen and human thrombin (Evicel);Sodium Chlorure (Physiological saline)
8 Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis Unknown status NCT02060305 Phase 4 Bevacizumab intra-articular injection
9 Assessment of a Knee Brace in Patients With Osteoarthritis Unknown status NCT02706106 Phase 4
10 Effectiveness of Trapeziometacarpal Splint Unknown status NCT02635932 Phase 4
11 Effects of Hyaluronic Acid vs. Hyaluronic Acid on Knee Osteoarthritis Unknown status NCT02625727 Phase 4
12 Intravenous Iron Sucrose in Arthroplasty Unknown status NCT02544828 Phase 4 Iron Sucrose 200mg;placebo
13 The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy Unknown status NCT02539069 Phase 4
14 The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) Unknown status NCT02539056 Phase 4
15 Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
16 Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline;0.9% Normal Saline
17 Validation of a Stress Device for the Knee Unknown status NCT02444663 Phase 4
18 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
19 Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE) Unknown status NCT02323451 Phase 4 Sodium Hyaluronate Injection
20 Comparing Conservative Therapies for the Alleviation of Knee Pain in Knee Osteoarthritis Unknown status NCT02320500 Phase 4
21 Tranexamic Acid in Knee Joint Surgery Unknown status NCT02278263 Phase 4 Tranexamic Acid;Normal saline (0.9% NaCl)
22 Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty Unknown status NCT02152917 Phase 4 Tranexamic acid;Floseal®
23 Intraarticular Xylitol Injections for Knee Osteoarthritis Unknown status NCT02104596 Phase 4
24 Daily Activity and Gait Analysis After Viscosupplement Injection Among Hip Osteoarthritis Patients Unknown status NCT02086474 Phase 4 Hyaluronan;Bupivacaine
25 The Effect of Spironolactone on Pain in Older People With Osteoarthritis Unknown status NCT02046668 Phase 4 spironolactone
26 Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy Unknown status NCT02000297 Phase 4
27 A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis Unknown status NCT01985165 Phase 4 Imrecoxib
28 Comparison of Femoral Nerve Catheter and Adductor Canal Block With Steroid Adjuvant in Total Knee Replacement (TKR) Unknown status NCT01973530 Phase 4
29 Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women Unknown status NCT01926158 Phase 4 Denosumb;Placebo (for denosumab)
30 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
31 Hip Viscosupplementation: What is the Best Dosage? Unknown status NCT01810809 Phase 4 1 ampoule of Hylan GF-20;2 ampoules of Hylan GF-20;3 ampoules of Hylan GF-20
32 Bone Forming at Prosthetic Surfaces. Fingerprint2 Unknown status NCT01623687 Phase 4
33 RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem Unknown status NCT01618084 Phase 4
34 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
35 Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Unknown status NCT01233739 Phase 4 Chondroitin sulfate;Placebo
36 Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI) Unknown status NCT01226615 Phase 4 Chondroitin sulphate (Condrosan®);Placebo
37 Prophecy Guide Outcomes in Total Knee Replacement Surgery Unknown status NCT01163708 Phase 4
38 Close Kinect Chain Exercise With Kinesio Taping in the Management of Patellofemoral Pain Syndrome Unknown status NCT02241148 Phase 4 Acetaminophen 500mg
39 Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty Unknown status NCT01027819 Phase 4
40 The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics Unknown status NCT00778076 Phase 4
41 Use of Cold and Compression Therapy With Total Knee Replacement Patients Unknown status NCT00712816 Phase 4
42 Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery Unknown status NCT00431509 Phase 4
43 The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator Unknown status NCT00422643 Phase 4 Sodium hyaluronate (hyaluronic acid)
44 Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee Unknown status NCT00393393 Phase 4 intra-articular injection of Hylan G-F 20
45 Effect of Flex-a-New on Osteoarthritis of the Knee Unknown status NCT00294801 Phase 4 flex-a-new (food supplement)
46 Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex Versus AGC Unknown status NCT00294528 Phase 4
47 Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk Unknown status NCT00194090 Phase 4 celecoxib
48 A Randomized Controlled Trial of Long Versus Short Wait For Primary Total Hip and Knee Arthroplasty Unknown status NCT00138892 Phase 4
49 Bipolar Sealer Aquamantys Use in Total Knee Replacement Unknown status NCT01736644 Phase 4
50 Comparison Between Anterior and Direct Lateral Approach in Total Hip Arthroplasty Unknown status NCT01578746 Phase 4

Search NIH Clinical Center for Joint Disorders

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Joint Disorders cell therapies at LifeMap Discovery.

Genetic Tests for Joint Disorders

Anatomical Context for Joint Disorders

MalaCards organs/tissues related to Joint Disorders:

38
Bone, Testes, Eye, Bone Marrow, Breast, Skin, Endothelial

Publications for Joint Disorders

Articles related to Joint Disorders:

(show top 50) (show all 109)
# Title Authors Year
1
Prevalence of tinnitus according to temporomandibular joint disorders and dental pain: The Korean National Population-based Study. ( 29314140 )
2018
2
Assessment of MRI findings and clinical symptoms in patients with temporomandibular joint disorders. ( 29451403 )
2018
3
Evaluation of Pain Syndromes, Headache, and Temporomandibular Joint Disorders in Children. ( 29153234 )
2018
4
Platelet-rich plasma for the therapeutic management of temporomandibular joint disorders: a systematic review. ( 29066000 )
2018
5
Pediatric Temporomandibular Joint Disorders. ( 29046237 )
2018
6
Analysis of synovial fluid visfatin level in temporomandibular joint disorders. ( 29385907 )
2018
7
Evaluation of a Patient With Temporomandibular Joint Disorders in Paget's Disease of Bone. ( 29361426 )
2018
8
Expression of chemerin in the synovial fluid of patients with temporomandibular joint disorders. ( 29331039 )
2018
9
The intravoxel incoherent motion MRI of lateral pterygoid muscle: a quantitative analysis in patients with temporomandibular joint disorders. ( 28332854 )
2017
10
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. ( 27697765 )
2017
11
The association between condylar bone changes revealed in cone beam computed tomography and clinical dysfunction index in patients with or without temporomandibular joint disorders. ( 28256415 )
2017
12
Regenerative Cells for the Management of Osteoarthritis and Joint Disorders: A Concise Literature Review. ( 29025215 )
2017
13
Phytomedicine in Joint Disorders. ( 28275210 )
2017
14
An Analysis of Pathological Activities of CCN Proteins in Joint Disorders: Mechanical Stretch-Mediated CCN2 Expression in Cultured Meniscus Cells. ( 27734404 )
2017
15
Comparative effectiveness of Low Level Laser therapy and Transcutaneous Electric Nerve Stimulation on Temporomandibular Joint Disorders. ( 29071032 )
2017
16
Efficacy of Temporomandibular Joint Arthrocentesis with Sodium Hyaluronate in the Management of Temporomandibular Joint Disorders: A Prospective Randomized Control Trial. ( 29038631 )
2017
17
Tinnitus in Temporomandibular Joint Disorders: Is it a Specific Somatosensory Tinnitus Subtype? ( 28452718 )
2017
18
Is There a Role for Oxidative Stress in Temporomandibular Joint Disorders? ( 29216476 )
2017
19
Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review. ( 28735350 )
2017
20
The effect of a functional appliance in the management of temporomandibular joint disorders in patients with juvenile idiopathic arthritis. ( 27716739 )
2017
21
Resveratrol, Potential Therapeutic Interest in Joint Disorders: A Critical Narrative Review. ( 28067817 )
2017
22
No evidence of association between articular status and clinical symptoms in patients with temporomandibular joint disorders. ( 28215435 )
2017
23
Association between composites of selected motion palpation and pain provocation tests for sacroiliac joint disorders. ( 28532864 )
2017
24
Quantification of cartilage oligomeric matrix protein (COMP) and a COMP neoepitope in synovial fluid of patients with different joint disorders by novel automated assays. ( 28473207 )
2017
25
Treatment of Temporomandibular Joint Disorders: The Unwanted Stepchild. ( 28667833 )
2017
26
Temporomandibular Joint Disorders as a Cause of Aural Fullness. ( 28103655 )
2017
27
The Role of Botulinum Toxin A in Treatment of Temporomandibular Joint Disorders: A Review. ( 29034269 )
2017
28
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). ( 26746234 )
2016
29
Blue rubber bleb nevus syndrome with knee joint disorder. ( 27117831 )
2016
30
WITHDRAWN: Occlusal adjustment for treating and preventing temporomandibular joint disorders. ( 26727292 )
2016
31
Osteoblastoma of the temporal articular tubercle misdiagnosed asA a temporomandibular joint disorder. ( 28043747 )
2016
32
Comparison of High-field and Low-field Magnetic Resonance Imaging of Stifle Joint Disorders in Dogs. ( 27760030 )
2016
33
Diagnosis of temporomandibular joint disorders: indication of imaging exams. ( 26832630 )
2016
34
Correlation between skeletal Class II and temporo-mandibular joint disorders: a literature review. ( 26938175 )
2016
35
Temporomandibular joint disorders. ( 28163470 )
2016
36
Recent Tissue Engineering Advances for the Treatment of Temporomandibular Joint Disorders. ( 27704395 )
2016
37
Synovial fluid matrix metalloproteinase-2 and -9 activities in dogs suffering from joint disorders. ( 26902805 )
2016
38
Cerezen device provides treatment for temporomandibular joint disorders day and night. ( 27338922 )
2016
39
An institutional survey for knowledge-based and self-awareness assessment in temporomandibular joint disorders among dental students. ( 27411654 )
2016
40
Feature selection and classification methodology for the detection of knee-joint disorders. ( 27000292 )
2016
41
Temporomandibular Joint Disorders and Orofacial Pain. ( 26614951 )
2016
42
Improved Therapeutic Efficacy in Bone and Joint Disorders by Targeted Drug Delivery to Bone. ( 27803481 )
2016
43
Evaluation of validity and reliability of a methodology for measuring human postural attitude and its relation to temporomandibular joint disorders. ( 26768173 )
2016
44
Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. ( 26888573 )
2016
45
Dentists' knowledge of occlusal splint therapy for bruxism and temporomandibular joint disorders. ( 27251967 )
2016
46
Comparison of Serum and Salivary Antioxidants in Patients with Temporomandibular Joint Disorders and Healthy Subjects. ( 26622281 )
2015
47
Bone and Joint Disorders in Acromegaly. ( 25633971 )
2015
48
Synovial plicae and temporomandibular joint disorders: surgical findings. ( 25795190 )
2015
49
Joint Arthroplasty With Osteochondral Grafting From the Knee for Posttraumatic or Degenerative Hand Joint Disorders. ( 26143968 )
2015
50
Can pterygoid plate asymmetry be linked to temporomandibular joint disorders? ( 26125003 )
2015

Variations for Joint Disorders

Expression for Joint Disorders

Search GEO for disease gene expression data for Joint Disorders.

Pathways for Joint Disorders

Pathways related to Joint Disorders according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 CSF1 IL11 IL17A IL18R1 IL1B IL1R1
2
Show member pathways
13.85 CSF1 IL11 IL17A IL18R1 IL1B IL1R1
3
Show member pathways
13.65 CSF1 IL11 IL17A IL18R1 IL1B IL1R1
4
Show member pathways
13.57 IL11 IL17A IL18R1 IL1B IL1R1 IL6
5
Show member pathways
13.33 CSF1 IL11 IL17A IL18R1 IL1B IL1R1
6
Show member pathways
13.28 CSF1 IL11 IL17A IL18R1 IL1B IL1R1
7
Show member pathways
13.21 CSF1 IL11 IL17A IL18R1 IL1B IL1R1
8
Show member pathways
13.03 IL18R1 IL1B IL1R1 IL1R2 IL1RN IL6
9 12.79 CSF1 IL1B IL1R1 IL1R2 TNF
10
Show member pathways
12.76 IL1B IL1R1 IL1R2 IL6 TIMP1 TNF
11
Show member pathways
12.65 IL17A IL18R1 IL1B IL6 TIMP1 TNF
12
Show member pathways
12.64 IL17A IL18R1 IL1B IL1R1 IL6 IL6R
13 12.61 IL17A IL1B IL1RN TNF TNFSF11
14
Show member pathways
12.44 IL17A IL1B IL6 TNF
15 12.44 IL1R1 IL1R2 IL6 TNF
16
Show member pathways
12.4 IL17A IL1B IL6 IL6R MMP3 TNF
17
Show member pathways
12.36 CSF1 IL1B IL6 TNF
18
Show member pathways
12.33 IL1B IL1R1 IL1R2 IL1RN
19
Show member pathways
12.31 IL1B IL1R1 IL6 TNF
20 12.29 IL1R2 IL6 MMP3 PLAU
21
Show member pathways
12.25 IL11 IL1B IL1R1 IL6 TNF
22 12.24 IL1B IL1RN IL6 IL6R TNF
23
Show member pathways
12.2 IL17A IL1B IL6 TNF
24 12.14 IL1B IL1R1 IL1R2 TNF
25 12.13 CSF1 IL1B IL1R1 TNF TNFSF11
26 12.06 IL1B IL1R1 IL6 TNF
27 12.04 CSF1 IL11 IL6 TNF
28 12.04 IL1B IL6 IL6R PLAU SERPINB2
29
Show member pathways
12.03 IL17A IL18R1 IL1B IL6 TNF
30 12.01 CSF1 IL18R1 IL1B IL6 MMP3 TNF
31 11.97 IL17A IL1B IL6 IL6R MMP3 TIMP1
32 11.96 IL1B IL1R1 IL1R2 IL6 TNF
33 11.95 IL1B IL1R1 PLAU TNF TNFSF11
34 11.92 IL6 IL6R TIMP1
35
Show member pathways
11.92 IL17A IL1B IL1R1 IL6 IL6R
36 11.91 IL1B IL6 TNF
37
Show member pathways
11.91 MMP3 TIMP1 TNF
38
Show member pathways
11.9 IL6 IL6R TIMP1 TNFSF11
39
Show member pathways
11.88 IL17A IL6 IL6R
40 11.87 IL17A IL1B IL1R1 TNF
41 11.82 CSF1 IL1B IL6 TNF
42 11.79 IL1B IL6 TNF
43
Show member pathways
11.75 IL1B IL6 MMP3 TNF
44 11.74 CSF1 IL11 IL1B IL1R1 IL1R2 IL6
45 11.72 IL1B IL6 PLAU TIMP1 TNF
46 11.68 MMP3 PLAU TIMP1
47
Show member pathways
11.66 IL11 IL6 IL6R
48 11.63 IL1B IL6 TNF
49 11.58 IL1B IL6 TNF
50 11.58 IL1B IL6 TNF TNFSF11

GO Terms for Joint Disorders

Cellular components related to Joint Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 CSF1 DKK1 IL11 IL17A IL1B IL1RN
2 extracellular region GO:0005576 9.53 CSF1 DKK1 IL11 IL17A IL1B IL1R1
3 interleukin-6 receptor complex GO:0005896 9.16 IL6 IL6R
4 plasma membrane GO:0005886 10.03 CSF1 DKK1 IL18R1 IL1R1 IL1R2 IL1RAPL2

Biological processes related to Joint Disorders according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.88 CSF1 IL17A IL1B IL1RN IL6 TNF
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 IL1B IL6 TNF TNFSF11
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 IL11 IL6 IL6R
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.82 IL11 IL6 TNF
5 positive regulation of JNK cascade GO:0046330 9.82 IL1B TNF TNFSF11
6 positive regulation of DNA binding transcription factor activity GO:0051091 9.81 IL1B IL6 TNF TNFSF11
7 immune response GO:0006955 9.81 IL17A IL18R1 IL1B IL1R1 IL1R2 IL1RN
8 response to glucocorticoid GO:0051384 9.8 IL1RN IL6 TNF
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.79 IL6 IL6R TNF
10 positive regulation of interferon-gamma production GO:0032729 9.76 IL18R1 IL1B TNF
11 monocyte chemotaxis GO:0002548 9.75 IL6 IL6R TNFSF11
12 regulation of osteoclast differentiation GO:0045670 9.67 TNF TNFSF11
13 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.67 IL1B TNF
14 positive regulation of interleukin-6 production GO:0032755 9.67 IL1B IL6 IL6R TNF
15 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.66 IL1B TNF
16 positive regulation of leukocyte chemotaxis GO:0002690 9.66 IL6 IL6R
17 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 IL1B TNF
18 osteoclast differentiation GO:0030316 9.65 CSF1 TNF TNFSF11
19 interleukin-6-mediated signaling pathway GO:0070102 9.64 IL6 IL6R
20 negative regulation of lipid storage GO:0010888 9.63 IL6 TNF
21 positive regulation of chemokine biosynthetic process GO:0045080 9.63 IL1B TNF
22 positive regulation of NF-kappaB import into nucleus GO:0042346 9.63 IL18R1 IL1B TNF
23 regulation of establishment of endothelial barrier GO:1903140 9.62 IL1B TNF
24 positive regulation of chemokine production GO:0032722 9.61 IL6 IL6R TNF
25 fever generation GO:0001660 9.6 IL1B IL1RN
26 positive regulation of fever generation GO:0031622 9.59 IL1B TNF
27 sequestering of triglyceride GO:0030730 9.57 IL1B TNF
28 positive regulation of osteoclast differentiation GO:0045672 9.56 CSF1 IL17A TNF TNFSF11
29 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.55 IL1B TNF
30 osteoclast proliferation GO:0002158 9.54 CSF1 TNFSF11
31 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.5 IL1R2 IL1RN IL6
32 cytokine-mediated signaling pathway GO:0019221 9.5 IL1B IL1R1 IL1R2 IL1RAPL2 IL6 IL6R
33 hepatic immune response GO:0002384 9.49 IL6 IL6R
34 regulation of receptor activity GO:0010469 9.36 CSF1 DKK1 IL11 IL17A IL1B IL1RN
35 positive regulation of gene expression GO:0010628 10 CSF1 DKK1 IL1B IL6 TNF
36 positive regulation of cell proliferation GO:0008284 10 CSF1 IL11 IL1B IL6 IL6R TIMP1

Molecular functions related to Joint Disorders according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.55 CSF1 DKK1 IL11 IL6 TIMP1
2 interleukin-1 binding GO:0019966 9.37 IL1R1 IL1R2
3 interleukin-6 receptor binding GO:0005138 9.32 IL6 IL6R
4 cytokine activity GO:0005125 9.28 CSF1 IL11 IL17A IL1B IL1RN IL6
5 interleukin-1, Type II, blocking receptor activity GO:0004910 9.26 IL1R2 IL1RAPL2
6 interleukin-1 receptor activity GO:0004908 9.26 IL18R1 IL1R1 IL1R2 IL1RAPL2
7 protein binding GO:0005515 10.31 CSF1 DKK1 IL11 IL17A IL18R1 IL1B

Sources for Joint Disorders

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16